Fagron NV (EBR:FAGR)

Market Cap	1.56B
Revenue (ttm)	871.96M
Net Income (ttm)	80.55M
Shares Out	72.84M
EPS (ttm)	1.10
PE Ratio	19.41
Forward PE	15.77
Dividend	0.35 (1.64%)
Ex-Dividend Date	May 21, 2024

Volume	35,603
Average Volume	59,960
Open	21.25
Previous Close	21.35
Day's Range	21.00 - 21.30
52-Week Range	15.14 - 21.30
Beta	0.21
RSI	73.53
Earnings Date	Jul 31, 2025

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointest...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 3,828
• Stock Exchange: Euronext Brussels
• Ticker Symbol: FAGR

Financial Performance

In 2024, Fagron NV's revenue was 871.96 million, an increase of 14.28% compared to the previous year's 762.99 million. Earnings were 80.55 million, an increase of 14.18%.